[
  {
    "question": "Female had optic neuritis with one non-enhancing periventricular lesion asking about mcdonald's criteria, OCB -ve",
    "option_a": "correctly states that the patient meets dissemination in space (DIS) due to the periventricular lesion accompanying optic neuritis. Option B is incomplete because it does not acknowledge the specific criteria being met. Option C is incorrect because it wrongly implies that dissemination in time (DIT) is fulfilled, and Option D is erroneous since at least one of the McDonald criterion components is satisfied.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuroimmunology",
    "explanation": "The McDonald criteria for multiple sclerosis (MS) require demonstration of dissemination in space (DIS) and dissemination in time (DIT). In patients with a clinically isolated syndrome such as optic neuritis, the presence of a characteristic lesion\u2014in this case, a single non-enhancing periventricular lesion\u2014fulfills the DIS requirement. However, since the lesion is non-enhancing (suggesting it is not active) and there is no additional evidence of a new lesion or relapse, DIT is not established. The negative oligoclonal bands (OCB) further confirm that CSF findings cannot be used to substitute for establishing dissemination in time. MS is an immune-mediated demyelinating disorder of the central nervous system. Inflammatory attacks cause focal areas of demyelination, commonly in periventricular white matter. Active lesions typically enhance on contrast MRI due to blood-brain barrier disruption, whereas non-enhancing lesions represent older, inactive plaques. This demyelination underlies the neurological deficits observed in MS. Optic neuritis is one of the most common initial presentations of MS and often prompts evaluation with brain MRI. The discovery of a periventricular lesion in a typical MS location supports the idea of DIS. However, without evidence of new lesion formation or clinical relapse, the full diagnostic criteria for MS (which require both DIS and DIT or their substitutes) are not wholly met at this time. Evaluation involves a detailed neurological history, MRI of the brain (and sometimes the spinal cord), and CSF analysis for the presence of OCB. Differential diagnoses include neuromyelitis optica spectrum disorder (NMOSD), acute disseminated encephalomyelitis (especially in a post-infectious setting), and other inflammatory or vascular conditions. Careful interpretation of lesion location, enhancement patterns, and clinical course is essential. For a patient with CIS and a low MRI lesion burden, current guidelines recommend observation with serial clinical evaluations and follow-up MRIs rather than immediate initiation of disease-modifying therapy (DMT). First-line DMTs are generally reserved for patients with clear evidence of MS. In pregnant or lactating patients, treatment considerations are cautious; agents like interferon-beta or glatiramer acetate may be used if needed, while high-risk medications are avoided. Option A correctly states that the patient meets dissemination in space (DIS) due to the periventricular lesion accompanying optic neuritis. Option B is incomplete because it does not acknowledge the specific criteria being met. Option C is incorrect because it wrongly implies that dissemination in time (DIT) is fulfilled, and Option D is erroneous since at least one of the McDonald criterion components is satisfied. 1. A single periventricular lesion in a patient with optic neuritis meets the DIS requirement according to McDonald criteria. 2. Non-enhancing lesions indicate older, inactive plaques and do not fulfill DIT. 3. Negative CSF OCB cannot substitute for evidence of temporal dissemination. Recent revisions of the McDonald criteria (2017) emphasize the role of MRI in demonstrating DIS and DIT. Advanced imaging techniques and ongoing research are improving early risk stratification and management decisions in CIS patients.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "19 YO man with confusion, MRI showed rt thalamic hyperintensity on FLAIR MRI, and around the 3rd ventricle (look like diencephalic syndrome to me) no fever",
    "option_a": "(testing for AQP4 antibodies) is incorrect because the clinical and radiological profile does not match NMOSD, in which AQP4 antibodies are typically positive and the lesion distribution is different. Option B (MOG antibody testing) is the correct approach given the presentation and imaging, while other options are not provided or are less relevant to this specific scenario.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "MOG antibody-associated disease (MOGAD) is increasingly recognized as a distinct demyelinating disorder from both MS and NMOSD. It frequently presents with encephalopathy or diencephalic syndromes, such as confusion and intractable vomiting, and often involves deep gray matter structures like the thalamus and regions around the third ventricle. MOGAD is mediated by antibodies directed against the myelin oligodendrocyte glycoprotein. These antibodies lead to demyelination with predilection for areas such as the thalamus, brainstem, and periventricular regions. Unlike NMOSD, which is associated with aquaporin-4 (AQP4) antibodies and typically involves the optic nerves and spinal cord, MOGAD often affects deep gray matter and presents with atypical imaging findings. In a 19-year-old man presenting with confusion and MRI findings of right thalamic hyperintensity along with lesions around the third ventricle, the clinical picture is more consistent with MOGAD rather than NMOSD. NMOSD usually presents with optic neuritis and longitudinally extensive transverse myelitis. Thus, the correct evaluation should include testing for MOG antibodies using a cell-based assay. The gold standard for diagnosing MOGAD is a cell-based assay to detect MOG IgG antibodies. Differential diagnoses include NMOSD (AQP4 antibody positive), acute disseminated encephalomyelitis (ADEM), and other encephalitic processes. MRI findings, clinical presentation, and serologic tests help differentiate these conditions. Acute management of MOGAD typically involves high-dose intravenous corticosteroids (e.g., IV methylprednisolone), which often lead to significant improvement. For refractory cases, plasma exchange or IVIG may be considered. In recurrent or severe cases, long-term immunosuppression (using agents like azathioprine, mycophenolate mofetil, or rituximab) may be indicated. In pregnant or lactating patients, corticosteroids are generally acceptable with appropriate monitoring, while the use of other immunosuppressants is balanced against potential fetal and neonatal risks. Option A (testing for AQP4 antibodies) is incorrect because the clinical and radiological profile does not match NMOSD, in which AQP4 antibodies are typically positive and the lesion distribution is different. Option B (MOG antibody testing) is the correct approach given the presentation and imaging, while other options are not provided or are less relevant to this specific scenario. 1. MOGAD should be suspected in young patients with deep gray matter involvement and atypical presentations such as confusion. 2. Isolated thalamic or diencephalic lesions are more characteristic of MOGAD than NMOSD. 3. Accurate diagnosis with a cell-based MOG antibody assay is critical for guiding appropriate immunotherapy. Recent studies have underscored the distinct immunopathogenesis of MOGAD compared to AQP4-positive NMOSD. Updated guidelines now recommend MOG antibody testing in patients with diencephalic syndromes and atypical MRI findings, ensuring that management is tailored to this unique entity.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Female with optic neuritis, she had one periventricular MRI lesion",
    "option_a": "(starting natalizumab) is overly aggressive and is reserved for patients with highly active relapsing",
    "option_b": "(starting interferon) is not indicated in a low",
    "option_c": "(observation until further investigation) is correct because it aligns with the recommended risk",
    "option_d": "further supports Option C as the best choice.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "In patients with a clinically isolated syndrome (CIS) such as optic neuritis with minimal MRI findings (only one periventricular lesion), current evidence supports a conservative approach. Immediate initiation of disease-modifying therapy (DMT) in low-risk cases is not routinely recommended. Optic neuritis is a common manifestation of demyelinating disease. However, when it is accompanied by only a single lesion on MRI, the risk for progression to definite MS is lower. The pathophysiological process in MS involves autoimmune-mediated demyelination, but the burden of disease in this case does not yet indicate active widespread inflammation. The patient\u2019s presentation with optic neuritis and a single periventricular lesion does not fulfill the requirements for definitive MS diagnosis because there is insufficient evidence for dissemination in time. Consequently, over-treatment with potent or even first-line DMTs may expose patients to unnecessary risks. The recommended approach is to monitor the patient with serial clinical evaluations and follow-up MRI studies to detect new lesions or relapses that would confirm dissemination in time (DIT). Differential diagnoses include isolated optic neuritis, MS, and other inflammatory demyelinating syndromes. Current guidelines advocate for observation with serial MRIs in patients with low lesion burden. Restart of treatment is considered only once there is evidence of dissemination in time or a clinical relapse. In pregnant or lactating patients, the decision to delay treatment may be further supported by the potential risks associated with DMTs. Option A (starting natalizumab) is overly aggressive and is reserved for patients with highly active relapsing-remitting MS. Option B (starting interferon) is not indicated in a low-risk CIS due to the relatively low risk of conversion at this point. Option C (observation until further investigation) is correct because it aligns with the recommended risk-adapted approach. The absence or inappropriateness of Option D further supports Option C as the best choice. 1. In CIS with a low lesion burden, observation with serial imaging is the preferred strategy. 2. Early aggressive treatment is not warranted without clear evidence of MS progression. 3. Reassessment over time is essential to establish dissemination in time. Recent guidelines emphasize a conservative, risk-adapted approach in patients with a CIS presenting with limited MRI findings. This strategy reduces unnecessary exposure to the potential adverse effects of DMTs while still monitoring for disease evolution.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with intractable vomiting and nausea admitted under GI and investigated with no identifiable cause, MRI done (image attached).\nWhich of the following is a core feature for the suspected diagnosis?",
    "option_a": "Optic neuritis",
    "option_b": "Cerebellitis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "The clinical scenario of intractable vomiting and nausea with an abnormal brain MRI (image provided) is highly suggestive of neuromyelitis optica spectrum disorder (NMOSD). Among the core clinical characteristics of NMOSD, optic neuritis is a recognized criterion despite the fact that the patient\u2019s presenting symptoms are primarily gastrointestinal. Recognizing core features beyond the immediate symptoms aids in establishing a unifying diagnosis. NMOSD is an astrocytopathy mediated by antibodies against aquaporin-4 (AQP4). This immune-mediated attack affects areas such as the optic nerves, spinal cord, and specific brain regions, including the area postrema, which when involved, leads to symptoms such as intractable vomiting and nausea. Optic neuritis results from similar pathogenic processes involving the optic nerves. Intractable vomiting in NMOSD is typically due to area postrema syndrome, one of the core clinical characteristics. Although the patient in this case may not present with optic neuritis, its presence is one of the recognized core features in the diagnostic criteria for NMOSD. Identifying such features is critical because NMOSD requires treatments that differ significantly from MS. Diagnosis of NMOSD relies on a combination of clinical presentation, MRI findings, and serologic testing for AQP4 antibodies. The differential diagnoses include multiple sclerosis (which has a different treatment approach), MOG antibody-associated disease, and other brainstem encephalitides. Detailed imaging and antibody testing help in distinguishing these conditions. Acute attacks in NMOSD are managed with high-dose intravenous corticosteroids. In patients who do not respond, plasma exchange is considered. For long-term management, immunosuppressants such as azathioprine, mycophenolate mofetil, or rituximab are used. In pregnancy, corticosteroids and certain immunosuppressants (like azathioprine) may be used with careful monitoring, while potentially teratogenic agents are avoided. Lactation considerations require balancing treatment efficacy with neonatal safety. Option A (optic neuritis) is correct because optic neuritis is a core clinical feature of NMOSD according to international diagnostic criteria. Option B (cerebellitis) is not a core characteristic of NMOSD and is rarely seen as a defining clinical sign in this context. The absence of additional relevant options further confirms the appropriateness of Option A. 1. NMOSD can present with diverse symptoms; intractable vomiting is a hallmark of area postrema involvement. 2. Optic neuritis, even if not present in every patient, remains a core diagnostic feature. 3. Differentiating NMOSD from MS is crucial due to differences in treatment and prognosis. Latest research and updated diagnostic criteria continue to underscore the distinct clinical spectrum of NMOSD. Recent studies highlight the importance of early AQP4 antibody testing and tailored immunosuppressive therapy, reinforcing the role of identifying core features such as optic neuritis in suspected cases.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young female patient with right leg weakness and incontinence, MRI report showed two periventricular lesions and T1 with contrast show one lesion enhancing and whole spine MRI showed T2 multiple small lesions.\nWhat is the diagnosis?",
    "option_a": "Multiple sclerosis",
    "option_b": "CIS",
    "option_c": "RIS",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disorder of the central nervous system that tends to affect young women. It is characterized by sporadic episodes of neurological deficits corresponding to demyelinated areas of the brain and spinal cord. MS is believed to result from an autoimmune attack in which T\u2011cells, along with other inflammatory mediators, target myelin and oligodendrocytes. The process produces multifocal areas of demyelination that are disseminated in time (different phases of activity) and space (different CNS regions). The presence of an enhancing lesion on T1\u2013weighted MRI indicates active inflammation while non-enhancing lesions represent older, inactive ones. Recent studies have reinforced the role of B\u2013cells and inflammatory cytokines, which has led to novel therapeutic agents. The patient\u2019s presentation with right leg weakness and urinary incontinence fits with spinal cord involvement. Periventricular lesions (the so\u2010called Dawson's fingers) along with spinal lesions on MRI further support the diagnosis. The combination of active (enhancing) and older lesions satisfies the McDonald criteria for dissemination in time and space. Diagnosis is based on clinical findings coupled with neuroimaging. The McDonald criteria describe the need for evidence of lesions disseminated in space (typically periventricular, juxtacortical, infratentorial or spinal lesions) and time (evidenced by simultaneous presence of enhancing and non-enhancing lesions, or a new lesion on follow\u2013up imaging). Differential diagnoses include clinically isolated syndrome (CIS), radiologically isolated syndrome (RIS), neuromyelitis optica spectrum disorders (NMOSD), and small vessel ischemic changes; however, the clinical picture along with classic MRI findings point to MS. For an acute relapse, high-dose intravenous corticosteroids (such as methylprednisolone 1 g/day for 3-5 days) are the first-line treatment. After stabilization, initiation of disease\u2013modifying therapies (DMTs) is recommended to reduce the frequency and severity of relapses. Special considerations are necessary for women who are pregnant or lactating; while some treatments like high-dose IV steroids can be used cautiously during pregnancy, many DMTs are contraindicated or require risk-benefit analysis. Option A (Multiple sclerosis) is the correct diagnosis as the imaging findings (multiple periventricular lesions with one enhancing lesion on T1 and additional spinal cord lesions on T2) along with clinical symptoms satisfy the diagnostic criteria for MS. Option B (Clinically Isolated Syndrome) would be considered if there had been a single clinical episode and did not meet dissemination in time. Option C (Radiologically Isolated Syndrome) applies to incidental MRI findings in asymptomatic individuals. 1. Dawson's fingers are the characteristic periventricular lesions seen in MS. 2. The coexistence of enhancing and non-enhancing lesions on MRI confirms active and older disease foci, satisfying dissemination in time. 3. MS is primarily a disease of young women with diverse neurological presentations. Recent updates to the McDonald diagnostic criteria (2017 revisions) emphasize that both brain and spinal cord imaging are critical in establishing the dissemination in space and time. Additionally, early initiation of DMTs has been shown in recent trials to alter long-term disability outcomes, underscoring the importance of early diagnosis and treatment.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young female patient with right leg weakness and incontinence, MRI report showed two periventricular lesions and T1 with contrast show one lesion enhancing and whole spine MRI showed T2 multiple small lesions.\nWhat is the next step in management?",
    "option_a": "Start treatment",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Once a diagnosis of MS is confirmed by clinical and radiological criteria, the next step is to address the active inflammatory process causing the patient\u2019s symptoms. MS relapses are managed with therapies that reduce inflammation and shorten recovery time. During an acute relapse, inflammatory cells infiltrate the CNS leading to active demyelination. This inflammatory reaction results in neurological deficits. High-dose corticosteroids accelerate recovery by reducing inflammatory cytokine production and stabilizing the blood-brain barrier. In this young female with right leg weakness and incontinence, the symptoms correlate with an active demyelinating lesion. The presence of an enhancing T1 lesion on MRI confirms active inflammation, indicating that prompt treatment is necessary to limit neurological damage. In MS relapses, the diagnosis is made based on clinical presentation and imaging. While alternative causes of acute neurological deficits (such as infections or vascular events) should be ruled out, the classic MRI findings in this scenario support an MS relapse. Differentiation from other demyelinating conditions can be achieved through comprehensive imaging and antibody testing (e.g., AQP4-IgG for NMOSD). First-line management of an acute MS relapse is high-dose intravenous corticosteroids (commonly IV methylprednisolone, 1 g/day for 3-5 days). If symptoms are severe or not responsive, plasmapheresis may be considered as a second-line intervention. For pregnant or lactating patients, high-dose steroids are generally considered, but the risks and benefits must be carefully weighed, and some DMT options might be contraindicated. Option A (Start treatment) is the correct next step. This refers primarily to initiating high-dose corticosteroid therapy for the acute relapse. Other potential options such as observation, further diagnostic work-up, or delayed treatment do not address the acute inflammation indicated by the imaging findings. 1. High-dose IV steroids are the mainstay for treating acute relapses in MS. 2. The presence of an enhancing lesion on MRI signals an active inflammatory process which demands prompt treatment. 3. Early intervention during a relapse can improve outcomes and limit lasting deficits. Recent clinical guidelines stress the importance of early intervention during an MS relapse and advocate for the use of IV corticosteroids as first-line therapy. Emerging studies support individualized treatment plans and careful consideration of pregnancy/lactation guidelines when choosing DMTs and acute therapies.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Which of the following tumors is mostly associated with opsoclonus-myoclonus?",
    "option_a": "Breast cancer",
    "option_b": "Ovarian cancer",
    "option_c": "Bronchogenic cancer",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Opsoclonus-myoclonus syndrome (OMS) is a rare neurological disorder characterized by involuntary, chaotic eye movements (opsoclonus) and myoclonic jerks, often accompanied by ataxia. It is frequently a paraneoplastic phenomenon, especially in the pediatric population. OMS is thought to be mediated by an autoimmune process triggered by a neoplasm. In children, it is classically associated with neuroblastoma. In adults, the syndrome is more commonly paraneoplastic and is most frequently linked to lung cancers, particularly small cell lung carcinoma (often referred to as bronchogenic carcinoma). Immune cross-reactivity between tumor antigens and neuronal structures is believed to underlie the disease mechanism. In adults presenting with opsoclonus-myoclonus, a high index of suspicion for an underlying malignancy is warranted. The rapid eye movements and myoclonic jerks can be accompanied by other neurological signs such as ataxia and behavioral changes. Identifying the underlying cancer is critical, as treatment of the tumor often leads to improvement in neurological symptoms. Diagnosis involves a detailed clinical evaluation along with appropriate imaging studies to identify an occult malignancy. Differentials include other movement disorders, cerebellar ataxia of different etiologies, or other paraneoplastic syndromes. Confirmatory tests may include onconeural antibody panels and imaging (CT chest or PET scan) to evaluate for lung cancer. Management of OMS involves two main strategies: 1) treating the underlying malignancy (which may involve surgery, chemotherapy, or radiotherapy) and 2) immunomodulation using corticosteroids, intravenous immunoglobulin (IVIG), or plasmapheresis. In pregnant or lactating patients, treatment plans need to carefully balance maternal benefit and fetal risk; for example, modifications in chemotherapy regimens and cautious use of steroids are required. Option A (Breast cancer) and Option B (Ovarian cancer) are less commonly associated with opsoclonus-myoclonus syndrome. Option C (Bronchogenic cancer) is correct because small cell lung carcinoma is the tumor most frequently linked to paraneoplastic OMS in adults. 1. In children with OMS, neuroblastoma is the most common associated malignancy, while in adults, look for small cell lung carcinoma. 2. Effective treatment of the underlying cancer can lead to significant improvement in neurological symptoms. 3. Onconeural antibodies can be useful in supporting the paraneoplastic origin of the syndrome. Recent research emphasizes the role of humoral and cellular immune responses in the pathogenesis of OMS. Current guidelines advocate for a multidisciplinary approach, including prompt oncologic screening in adults with OMS symptoms and the use of immunosuppressive therapies to mitigate neurological damage.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "The periventricular white lesion typical of MS, follows a specific pattern in the distribution of which following structure?",
    "option_a": "Oligodendrocytes cell body.",
    "option_b": "Arterioles.",
    "option_c": "Venules.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "In multiple sclerosis, the characteristic periventricular white matter lesions, often described as 'Dawson's fingers', are oriented along the course of small blood vessels within the brain. MS lesions typically form around small veins (venules) due to the inflammatory process targeting perivenular regions. The venous distribution is a hallmark of MS pathology which reflects the immune-mediated attack on the central nervous system. This perivenular pattern distinguishes MS lesions from other white matter abnormalities. On MRI, these lesions are best seen adjacent to the lateral ventricles and radiate perpendicularly, corresponding to the distribution of the small venules. Recognizing this perivenular distribution helps confirm the diagnosis of MS. Differentiating MS plaques from other white matter lesions (such as those due to small vessel ischemic changes) relies on their characteristic distribution and appearance on MRI. MS lesions, often oriented along venules, help distinguish them from ischemic lesions, which typically involve arterial territories and have different morphology. While the distribution of lesions itself does not dictate treatment, recognizing the pattern is crucial for diagnosis. MS management includes acute relapse treatment with high-dose corticosteroids as well as initiation of disease-modifying therapies. In pregnant patients, treatment decisions require careful consideration with some therapies being contraindicated during pregnancy or lactation. Option A (Oligodendrocytes cell body) is incorrect because although these cells are affected in MS, the distribution pattern described on MRI relates to the venous anatomy. Option B (Arterioles) does not account for the imaging pattern. Option C (Venules) is the correct answer, reflective of Dawson\u2019s fingers \u2013 lesions arranged around small veins. 1. Dawson\u2019s fingers are a classic radiological sign in MS, demonstrating lesions oriented perpendicular to the lateral ventricles along venules. 2. Recognizing the perivenular pattern on MRI aids in distinguishing MS lesions from other white matter pathologies. 3. MS is characterized by multifocal demyelinating lesions that follow specific vascular distributions. Recent advances in MRI techniques have enhanced the ability to visualize the perivenular distribution of lesions, supporting the hypothesis of venule-centered inflammation in MS. Updated neuroimaging criteria continue to emphasize the importance of Dawson\u2019s fingers in the diagnostic process.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young male brought by his father with complain of catatonia, psychosis, seizure, and dysautonomia. Which of the following antibodies is most likely associated with his condition?",
    "option_a": "Anti-GABA",
    "option_b": "Anti-NMDA",
    "option_c": "Anti-CASPR 2",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Anti\u2010NMDA receptor encephalitis is an autoimmune encephalitis in which antibodies target NMDA receptors in the brain. It typically presents in young individuals with prominent psychiatric symptoms (eg, psychosis, catatonia), seizures, and dysautonomia. While it is more common in young females (often associated with ovarian teratomas), it can also occur in males. The pathogenic antibodies bind to the NR1 subunit of the NMDA receptor, causing receptor internalization and synaptic dysfunction. This disrupts normal neurotransmission, leading to the neuropsychiatric manifestations observed. The dysautonomia arises from involvement of autonomic centers in the brain, and inflammatory mediators further contribute to the clinical picture. Patients often present with an initial phase dominated by psychiatric symptoms (anxiety, agitation, delusions, or catatonia) followed by the development of seizures, movement disorders, and autonomic instability. Recognizing this constellation of symptoms is crucial, as early diagnosis and treatment are linked to a better prognosis. Diagnosis is supported by cerebrospinal fluid (CSF) analysis showing a mild lymphocytic pleocytosis and the presence of oligoclonal bands. The definitive test is the detection of anti\u2010NMDA receptor antibodies in the CSF (which is more sensitive than serum testing). Differential diagnoses include viral encephalitis (such as herpes simplex virus encephalitis), other autoimmune encephalitides, and primary psychiatric disorders. First\u2010line treatment includes high\u2010dose corticosteroids, intravenous immunoglobulin (IVIG), and plasma exchange. If patients do not respond, second\u2010line immunosuppressants such as rituximab or cyclophosphamide may be used. In cases of an associated neoplasm (eg, ovarian teratoma), tumor removal is imperative. In pregnancy and lactation, corticosteroids and IVIG are generally considered safe, but teratogenic medications like cyclophosphamide require caution, and a multidisciplinary discussion is advised. Option A (Anti\u2010GABA) is incorrect as antibodies against GABA receptors are implicated in other encephalitides that often present with refractory seizures. Option C (Anti\u2010CASPR2) is associated with conditions like Morvan syndrome and neuromyotonia. Option B (Anti\u2010NMDA) is correct given the clinical presentation described. 1. In young patients with new-onset psychosis accompanied by seizures and autonomic disturbances, consider autoimmune encephalitis. 2. CSF antibody testing has a higher sensitivity than serum testing for anti\u2010NMDA receptor encephalitis. 3. Early immunotherapy significantly improves clinical outcomes. Recent studies and guidelines stress early recognition and prompt initiation of immunotherapy. The use of CSF antibody detection remains the standard for diagnosis, and ongoing research is focused on optimizing second-line immunosuppressive strategies to reduce relapse rates.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Patient diagnosed with opsoclonus-myoclonus-ataxia syndrome. Which of the following antibodies most likely to be identified in laboratory workup?",
    "option_a": "Anti-Ri",
    "option_b": "Anti-Hu",
    "option_c": "Anti-Yo",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Opsoclonus\u2010myoclonus\u2010ataxia syndrome (OMS) is a rare neurological disorder characterized by rapid, involuntary, multidirectional eye movements (opsoclonus), myoclonic jerks, and ataxia. It is often paraneoplastic, particularly in adults with underlying malignancies such as breast or lung cancer, and in children with neuroblastoma. OMS is believed to result from an autoimmune reaction, where onconeural antibodies cross-react with antigens in the nervous system. Anti\u2010Ri antibodies (also known as ANNA\u20102) have been frequently associated with OMS and are thought to mediate neuronal dysfunction in brainstem and cerebellar circuits. Clinically, patients with OMS exhibit chaotic eye movements, involuntary muscle jerks, and an unsteady gait. In children, when OMS is paraneoplastic (eg, due to neuroblastoma), prompt investigation for an underlying tumor is essential. In adults, the presence of anti\u2010Ri antibodies should trigger a work-up for a hidden malignancy. Diagnosis is made clinically, supported by antibody testing. A comprehensive paraneoplastic panel is used, and in cases where OMS is suspected, anti\u2010Ri antibody testing is prioritized. Differential diagnoses include other paraneoplastic neurological syndromes such as those mediated by anti\u2010Hu (typically associated with sensory neuropathies) and anti\u2010Yo (associated with cerebellar degeneration). Management involves both immunotherapy (such as corticosteroids, IVIG, or plasmapheresis) and thorough oncologic evaluation with treatment of the underlying malignancy. In refractory cases, rituximab can be considered. For pregnant or lactating patients, IVIG and corticosteroids are generally safe alternatives, though management should be individualized in coordination with obstetric care. Option A (Anti\u2010Ri) is correct as it is most commonly associated with opsoclonus\u2010myoclonus syndrome, particularly in adult cases. Option B (Anti\u2010Hu) is more common in paraneoplastic syndromes with sensory neuronopathy, and Option C (Anti\u2010Yo) is typically linked to paraneoplastic cerebellar degeneration. 1. Opsoclonus (chaotic eye movements) combined with myoclonus and ataxia is a red flag for a paraneoplastic syndrome. 2. In children with OMS, always investigate for neuroblastoma. 3. Anti\u2010Ri positive OMS in adults should prompt a search for an underlying malignancy. Latest guidelines recommend an early and aggressive work-up for malignancy in cases of paraneoplastic OMS. Research continues to elucidate the immunopathogenic mechanisms, and newer immunomodulatory therapies are being evaluated to improve long-term outcomes.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young man diagnosed presented with history of left eye optic neuritis. He was planned to start Teriflunomide. There is no previous history of neurological symptoms. He is not interested in starting the treatment. Which of the following true regarding the suspected differential diagnosis?",
    "option_a": "Bilateral onset should suspect diagnosis other than multiple sclerosis",
    "option_b": "Incomplete visual recovery should suspect diagnosis other than multiple sclerosis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Optic neuritis is a common initial manifestation of multiple sclerosis (MS), typically presenting as a unilateral, painful visual loss that recovers substantially. In contrast, alternative demyelinating conditions, such as neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disorders, may present with atypical features. In MS, demyelination of the optic nerve is immune-mediated and is typically limited and self-resolving due to remyelination and neural plasticity, leading to good recovery. Other antibody-mediated disorders (eg, NMOSD) involve severe astrocyte injury (mediated by anti-AQP4 antibodies) or oligodendrocyte damage (with anti-MOG antibodies), often resulting in more profound and incomplete recovery. Most cases of MS-associated optic neuritis are unilateral with a high rate of visual recovery. Incomplete recovery of vision, however, should raise suspicion for an alternative diagnosis such as NMOSD or MOG-antibody associated disease, both of which tend to have a more severe clinical course and poorer visual recovery. Evaluation includes a detailed history, ophthalmologic exam, and MRI of the brain and orbits. Laboratory tests are directed towards antibody profiles (such as AQP4 for NMOSD or MOG antibodies) if recovery is incomplete or if bilateral involvement is present. Differential diagnoses include ischemic optic neuropathy, compressive lesions, and other inflammatory conditions. First-line treatment for MS-related optic neuritis typically involves high-dose intravenous corticosteroids followed by an oral taper. For NMOSD, management includes acute therapy with steroids and plasma exchange, followed by long-term immunosuppression (eg, azathioprine, mycophenolate mofetil, or rituximab). For women who are pregnant or lactating, treatment choices must be carefully weighed; corticosteroids and IVIG are generally safe, while many immunosuppressants pose risks and require multidisciplinary management. Option A states that a bilateral onset would suggest a diagnosis other than MS \u2013 which is true in general, as bilateral optic neuritis is more suggestive of NMOSD or MOG-associated disease. Option B, the marked answer, asserts that incomplete visual recovery should raise suspicion for a diagnosis other than MS. This is also accurate since MS optic neuritis usually recovers well. In this specific context, where the patient has a unilateral episode with the possibility of MS, the key differentiator is that incomplete recovery is atypical for MS, thereby supporting option B as the correct consideration for alternative diagnoses. 1. MS-related optic neuritis usually presents unilaterally with near-complete recovery. 2. Both bilateral involvement and incomplete visual recovery are red flags that should prompt evaluation for alternative diagnoses such as NMOSD or MOG antibody-associated disease. 3. Detailed antibody testing (AQP4, MOG) is essential if atypical features are present. Recent studies reinforce that complete or near-complete recovery is expected in typical MS optic neuritis, whereas persistent deficits should prompt reconsideration of the diagnosis with appropriate serologic and imaging investigations. Updated guidelines advocate for early differentiation using both clinical and laboratory parameters to tailor treatment accordingly.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "A 30s-year-old lady who presented to the ER with worsening weakness on all 4 extremities and sensory symptoms. She was diagnosed with multiple sclerosis three months ago for an optic neuritis and she was started on Natalizumab due to highly active Ms. MRI done (image attached). Which of the following laboratory investigations should be sent based on the suspected differential diagnosis? (NMOSP)",
    "option_a": "JC virus from CSF",
    "option_b": "Serum ACE",
    "option_c": "Serum AQP-4",
    "option_d": "Oligoclonal bands",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Patients with multiple sclerosis (MS) who are treated with natalizumab are at risk for developing progressive multifocal leukoencephalopathy (PML), a rare but serious demyelinating disease caused by reactivation of the JC virus. Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier by blocking the \u03b14-integrin. This immunomodulatory effect, while beneficial for reducing MS relapses, can impair central nervous system (CNS) immune surveillance and allow JC virus reactivation, leading to PML. The JC virus infects oligodendrocytes and causes widespread demyelination. A patient on natalizumab presenting with new, progressive neurological deficits (eg, worsening weakness in all extremities and sensory symptoms) should raise suspicion for PML. The clinical deterioration is typically subacute and can mimic an MS relapse, but the pattern of multifocal neurological deficits and the context of natalizumab use are red flags. The investigation of choice in suspected PML is the polymerase chain reaction (PCR) assay for JC virus in the CSF. Brain MRI findings can also suggest PML, often showing multifocal non-enhancing white matter lesions without mass effect. Differential diagnoses include an MS relapse (which would typically have enhancing lesions and different distribution), neuromyelitis optica spectrum disorder (assessed via serum AQP4 antibodies), and other inflammatory or infectious conditions. If PML is confirmed, natalizumab must be promptly discontinued. There is no definitive antiviral treatment; management focuses on immune reconstitution, which may be complicated by immune reconstitution inflammatory syndrome (IRIS). Plasmapheresis may be used to accelerate natalizumab clearance. In pregnant or lactating women, the management of PML is highly challenging and requires a multidisciplinary approach balancing maternal neurological risk and potential fetal/neonatal effects. Option A (JC virus from CSF) is correct because the detection of JC virus DNA by PCR in the CSF is the gold standard for diagnosing PML. Option B (Serum ACE) is used to evaluate sarcoidosis. Option C (Serum AQP-4) is used in the workup of neuromyelitis optica spectrum disorder, and Option D (Oligoclonal bands) is a marker seen in MS rather than PML. 1. Natalizumab is strongly associated with an increased risk of PML due to JC virus reactivation. 2. Early recognition and diagnosis of PML using CSF JC virus PCR are vital for preventing further neurological decline. 3. MRI plays a key role in the identification of PML lesions, which typically do not enhance and are found in the subcortical white matter. Contemporary research has focused on the risk stratification of natalizumab-treated patients using the JC virus antibody index and other biomarkers. Updated guidelines emphasize vigilant monitoring for PML with regular MRI and clinical evaluations, and prompt cessation of natalizumab if PML is suspected.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Female patient known case of relapsing remitting multiple sclerosis maintained on DMT presented with new limb weakness and numbness. Diagnosis of multiple sclerosis established. She started on high dose IV Methylprednisolone but with no improvement. Which of the following is the next step in the management?",
    "option_a": "IV immunoglobulin",
    "option_b": "Plasma exchange",
    "option_c": "ACTH gel",
    "option_d": "Oral steroid",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "In relapsing-remitting multiple sclerosis (MS), acute relapses are typically managed with high-dose intravenous corticosteroids. When patients do not respond adequately to steroids, escalation of therapy is warranted. Plasma exchange (PLEX) is indicated in steroid-refractory acute relapses to remove pathogenic autoantibodies and inflammatory mediators. MS is characterized by immune-mediated demyelination within the central nervous system. During an acute relapse, inflammatory cells breach the blood-brain barrier causing multifocal demyelination. When high-dose corticosteroids fail to control this inflammatory process, plasma exchange can help remove circulating antibodies and immune complexes that contribute to ongoing tissue injury. The patient\u2019s new onset of limb weakness and numbness despite steroid treatment indicates a severe relapse that is not responsive to first\u2010line therapy. This clinical scenario is a classic indication for plasma exchange to mitigate continued neurological damage. Diagnosis of an MS relapse is based on clinical presentation and supported by neuroimaging (MRI) showing new or enhancing lesions. In the context of an inadequate response to steroids, the stability of imaging findings further supports the need for an alternative therapeutic approach. Differential diagnoses include pseudo-relapses (e.g., due to infection or heat exposure), which should be ruled out by careful clinical evaluation. First-line management for an acute MS relapse is high-dose IV methylprednisolone (typically 1 gram daily for 3-5 days). For patients who do not improve after steroids, plasma exchange is the recommended second-line treatment. In pregnant or lactating patients, both corticosteroids and plasma exchange can be used; however, clinicians must weigh the benefits and potential risks\u2014pregnancy itself is not a contraindication for plasma exchange when clinically indicated. Option A (IV immunoglobulin) is not the standard escalation for steroid-refractory relapses in MS. Option B (Plasma exchange) is correct as it is the recommended next step. Option C (ACTH gel) is not a first- or second\u2010line therapy in this scenario. Option D (Oral steroid) is usually less effective than IV steroids and is not appropriate after failure of high-dose IV therapy. 1. Plasma exchange is reserved for severe, steroid-refractory MS relapses. 2. Early escalation to plasma exchange may help limit permanent neurological deficits in severe relapses. Recent guidelines and studies support the use of plasma exchange in patients with steroid-resistant relapses, as it can lead to improved functional outcomes. The American Academy of Neurology and other bodies have recognized plasma exchange as an evidence-based treatment option in these scenarios.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Middle age man presented to the outpatient clinic due to history of peripheral neuropathy. Past medical significant for asthma and recurrent sinusitis. Labs showed Positive P-ANCA. Which of the followings is the most likely diagnosis?",
    "option_a": "Polyarteritis nodosa.",
    "option_b": "Wegener granulomatosis",
    "option_c": "Churg strauss syndrome",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a small- to medium-vessel vasculitis that typically affects patients with a history of asthma and allergic rhinitis, along with systemic symptoms such as peripheral neuropathy. EGPA is characterized by eosinophil-rich granulomatous inflammation and necrotizing vasculitis affecting small- to medium-sized vessels. The presence of P-ANCA (perinuclear-anti-neutrophil cytoplasmic antibodies) in many patients further supports an autoimmune contribution, which results in inflammatory damage to nerves, lungs, and other tissues. This patient\u2019s clinical profile including asthma, recurrent sinusitis, and peripheral neuropathy, along with laboratory evidence of a positive P-ANCA, is most consistent with EGPA. The involvement of peripheral nerves manifests as a mononeuritis multiplex, contributing to the patient\u2019s neuropathic symptoms. The diagnosis of EGPA involves a combination of clinical criteria (asthma, sinusitis, peripheral neuropathy), laboratory findings (eosinophilia, positive P-ANCA), and, in some cases, tissue biopsy. Differential diagnoses include polyarteritis nodosa (typically ANCA-negative and without asthma) and granulomatosis with polyangiitis (Wegener granulomatosis, which is more often C-ANCA positive and involves the kidneys and upper respiratory tract without the marked eosinophilia seen in EGPA). The cornerstone of EGPA management is high-dose glucocorticoids, often supplemented with immunosuppressive agents such as cyclophosphamide or rituximab in severe cases. For patients with milder disease, steroid-sparing agents may be utilized. In pregnant or lactating patients, careful selection of immunosuppressants is required; glucocorticoids are generally considered safe, while other agents need to be used with caution due to potential teratogenic effects. Option A (Polyarteritis nodosa) is less likely because it typically does not involve the lungs, is not associated with asthma, and is generally ANCA negative. Option B (Wegener granulomatosis) is more commonly associated with upper respiratory tract involvement and is typically C-ANCA positive, which does not match this patient\u2019s profile. Option C (Churg-Strauss syndrome/EGPA) correctly fits the clinical presentation and laboratory findings. 1. The combination of asthma, sinusitis, peripheral neuropathy, and P-ANCA positivity is highly suggestive of EGPA. 2. EGPA is one of the few vasculitides where prominent eosinophilia and allergic features are key diagnostic clues. Recent research has led to the use of targeted therapies such as mepolizumab, an anti-IL-5 monoclonal antibody, which has shown promise in reducing corticosteroid dependence and controlling eosinophilic inflammation in EGPA.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "A 30-year-old male known case of DM 1 presented 3 months ago with optic neuritis and started on one of DMT at that time as a case of multiple sclerosis. He presented now with 3 days history of blurred vision. Examination and brain MRI are stable compared with the previous documentation.\nWhich DMT is likely responsible for this presentation?",
    "option_a": "Fingolimod",
    "option_b": "Teriflunomide",
    "option_c": "Interferon",
    "option_d": "Natalizumab",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroimmunology",
    "explanation": "Fingolimod is a disease-modifying therapy (DMT) used in relapsing-remitting MS. It functions as a sphingosine-1-phosphate (S1P) receptor modulator and is known to have ocular side effects, most notably macular edema, which can manifest as blurred vision. Fingolimod sequesters lymphocytes in lymph nodes by modulating S1P receptors, thereby reducing their migration into the CNS. However, this modulation of S1P receptors can also increase vascular permeability in the retina, predisposing patients\u2014especially those with risk factors like diabetes\u2014to develop macular edema. The patient, who is a known diabetic (a risk factor for macular edema), presents with blurred vision and has stable MRI findings, making a new MS lesion less likely. This clinical scenario points to a drug-induced side effect rather than disease progression, with fingolimod being the prime suspect. In patients on fingolimod who develop visual symptoms, an ophthalmologic evaluation is essential. Optical coherence tomography (OCT) is the diagnostic modality of choice to detect and monitor macular edema. Differential diagnoses include optic neuritis (which would typically show MRI changes) and diabetic retinopathy; however, the temporal association with fingolimod initiation and the absence of MRI lesion progression support a diagnosis of fingolimod-induced macular edema. Management involves prompt ophthalmologic assessment. If macular edema is confirmed, the drug may need to be discontinued or suspended, and treatment of the edema (e.g., with topical or systemic therapies) may be initiated as per ophthalmology recommendations. Alternatives to fingolimod should be considered. In pregnant or lactating patients, fingolimod is contraindicated due to its teratogenic potential and should be avoided. Option A (Fingolimod) is correct because it is the only DMT among the options known to cause macular edema. Option B (Teriflunomide) and Option C (Interferon) do not have macular edema as a well-known side effect. Option D (Natalizumab) primarily carries a risk of progressive multifocal leukoencephalopathy (PML) rather than ocular complications. 1. Always screen MS patients on fingolimod for signs of macular edema, particularly if they have additional risk factors such as diabetes mellitus. 2. A normal brain MRI in this context helps differentiate drug-induced macular edema from an MS relapse. Recent studies and post-marketing surveillance have reinforced the association between fingolimod and macular edema. Current guidelines recommend baseline and periodic ophthalmologic examinations for patients on fingolimod, with a lower threshold for evaluation in diabetic patients.",
    "exam_year": "2023",
    "exam_type": "Part I",
    "image_url": "page_10.png"
  },
  {
    "question": "Elderly male with painful sensory symptoms, progressive loss coordination and he had sensory ataxia. What is the possible antibody to be associated with his condition?",
    "option_a": "Anti-Yo.",
    "option_b": "Anti-Hu.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Paraneoplastic neurological syndromes are a group of disorders caused by immune responses to neoplasms outside the nervous system. Among these, a painful sensory neuropathy with sensory ataxia in an elderly male is classically associated with anti-Hu antibodies. Anti-Hu antibodies target antigens found in both tumor cells (often small cell lung cancer) and neurons, particularly dorsal root ganglia. This autoimmune response leads to neuronal damage and manifests as sensory neuronopathy, characterized by painful dysesthesias and ataxia. The patient\u2019s presentation of painful sensory symptoms and loss of coordination, coupled with a paraneoplastic profile (typically seen in older individuals, often males, with an underlying malignancy), aligns best with an anti-Hu-associated sensory neuronopathy rather than a cerebellar syndrome. Workup for suspected paraneoplastic syndromes includes detailed neurological evaluation, serological testing for antineuronal antibodies (such as anti-Hu), and imaging studies (chest CT, PET scan) to identify an occult malignancy. Differential diagnoses include vitamin deficiency neuropathies, diabetic neuropathy, and other paraneoplastic syndromes such as anti-Yo associated cerebellar degeneration (which typically presents in women with breast or gynecologic cancers). The primary management involves treating the underlying malignancy along with immunotherapy, which might include corticosteroids, IV immunoglobulin, or plasma exchange. However, the neurological deficits are often less reversible compared to other conditions. In the context of pregnancy and lactation (less applicable in an elderly male), treatment strategies would need to be carefully balanced with fetal/neonatal safety; however, the management of paraneoplastic syndromes typically prioritizes oncological control and immunosuppression. Option A (Anti-Yo) is predominantly associated with paraneoplastic cerebellar degeneration in women with breast or gynecologic cancers. Option B (Anti-Hu) is correctly identified as the antibody commonly linked with sensory neuronopathy and paraneoplastic syndromes, particularly in older male patients often with small cell lung carcinoma. 1. Anti-Hu antibodies are a hallmark of paraneoplastic sensory neuronopathy, often prompting a search for an occult malignancy. 2. Paraneoplastic neurological syndromes often precede the diagnosis of the underlying cancer, making early recognition critical. Recent research emphasizes the importance of early detection of anti-Hu antibodies for prompt cancer workup, as well as the potential benefits, though limited, of immunomodulatory therapies. Advances in cancer therapies and immunotherapies continue to refine the management of paraneoplastic syndromes.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "What is the best way to prevent PML in patients with MS in whom will be started on Natalizumab?",
    "option_a": "Annual MRI",
    "option_b": "Pretreatment JC virus titer levels screen.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroimmunology",
    "explanation": "Natalizumab is a highly effective monoclonal antibody used in multiple sclerosis (MS) that works by inhibiting lymphocyte migration into the central nervous system. However, its mechanism predisposes patients to reactivation of latent JC virus, which can cause progressive multifocal leukoencephalopathy (PML). Preventing PML largely depends on risk stratification before treatment initiation. Natalizumab binds to \u03b14-integrin, blocking the adhesion of lymphocytes to vascular endothelium, thereby reducing inflammatory cell entry into the CNS. In patients who have been exposed to the JC virus, this immune modulation may allow reactivation of the virus leading to PML \u2013 a demyelinating disease caused by lytic infection of oligodendrocytes. Screening for JC virus antibodies helps stratify this risk. PML presents with progressive neurological deficits that can mimic MS exacerbations but with a rapid and often fatal course. Clinicians screen for anti\u2013JC virus antibody levels before starting natalizumab to identify patients at higher risk. Before natalizumab initiation, testing the patient\u2019s serum for antibodies to JC virus (and, if available, calculating an index value) is essential. This, along with periodic MRI monitoring, is used to detect early signs of PML. Differential diagnoses include MS relapse, other opportunistic infections, or drug-induced leukoencephalopathy. First-line prevention involves risk stratification with pre-treatment JC virus antibody screening. In patients who are JC virus\u2013antibody negative, natalizumab can be used with periodic re\u2010evaluation. A tiered approach includes: (1) Pre-treatment screening; (2) Regular monitoring (MRI every 6\u201312 months, as recommended in updated guidelines); (3) Discontinuation or switching therapy in patients with high antibody titers. In special populations (pregnant or lactating women), the decision to use natalizumab requires a careful risk\u2013benefit analysis and thorough counseling, as its use is generally reserved for patients with highly active disease, with appropriate monitoring. Option A (Annual MRI) is used for monitoring but does not prevent PML. Options C and D are not provided and/or not relevant. Option B, \u201cPretreatment JC virus titer levels screen,\u201d is the correct preventive measure as it directly assesses the patient\u2019s risk prior to starting the drug. \u2022 JC virus antibody screening is mandatory before starting natalizumab. \u2022 A high JC virus antibody index correlates with increased risk for PML. \u2022 Regular MRI monitoring is essential for early detection of PML but does not prevent it. Recent guidelines emphasize the importance of JC virus antibody index levels along with periodic imaging to mitigate risk. Large cohort studies continue to refine the risk models for PML in natalizumab-treated patients, and current recommendations support individualized risk assessment particularly in women of childbearing potential.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with MS on DMT developed Hyperthyroidism. What is the most likely used medication?",
    "option_a": "Fingolimod",
    "option_b": "Teriflunomide",
    "option_c": "Alemtuzumab",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Natalizumab is a highly effective monoclonal antibody used in multiple sclerosis (MS) that works by inhibiting lymphocyte migration into the central nervous system. However, its mechanism predisposes patients to reactivation of latent JC virus, which can cause progressive multifocal leukoencephalopathy (PML). Preventing PML largely depends on risk stratification before treatment initiation. Natalizumab binds to \u03b14-integrin, blocking the adhesion of lymphocytes to vascular endothelium, thereby reducing inflammatory cell entry into the CNS. In patients who have been exposed to the JC virus, this immune modulation may allow reactivation of the virus leading to PML \u2013 a demyelinating disease caused by lytic infection of oligodendrocytes. Screening for JC virus antibodies helps stratify this risk. PML presents with progressive neurological deficits that can mimic MS exacerbations but with a rapid and often fatal course. Clinicians screen for anti\u2013JC virus antibody levels before starting natalizumab to identify patients at higher risk. Before natalizumab initiation, testing the patient\u2019s serum for antibodies to JC virus (and, if available, calculating an index value) is essential. This, along with periodic MRI monitoring, is used to detect early signs of PML. Differential diagnoses include MS relapse, other opportunistic infections, or drug-induced leukoencephalopathy. First-line prevention involves risk stratification with pre-treatment JC virus antibody screening. In patients who are JC virus\u2013antibody negative, natalizumab can be used with periodic re\u2010evaluation. A tiered approach includes: (1) Pre-treatment screening; (2) Regular monitoring (MRI every 6\u201312 months, as recommended in updated guidelines); (3) Discontinuation or switching therapy in patients with high antibody titers. In special populations (pregnant or lactating women), the decision to use natalizumab requires a careful risk\u2013benefit analysis and thorough counseling, as its use is generally reserved for patients with highly active disease, with appropriate monitoring. Option A (Annual MRI) is used for monitoring but does not prevent PML. Options C and D are not provided and/or not relevant. Option B, \u201cPretreatment JC virus titer levels screen,\u201d is the correct preventive measure as it directly assesses the patient\u2019s risk prior to starting the drug. \u2022 JC virus antibody screening is mandatory before starting natalizumab. \u2022 A high JC virus antibody index correlates with increased risk for PML. \u2022 Regular MRI monitoring is essential for early detection of PML but does not prevent it. Recent guidelines emphasize the importance of JC virus antibody index levels along with periodic imaging to mitigate risk. Large cohort studies continue to refine the risk models for PML in natalizumab-treated patients, and current recommendations support individualized risk assessment particularly in women of childbearing potential.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young male had isolated single attack of focal neurological deficit. He did not started on DMT.\nWhat is the percentage of having second attack? (They did not mention the term benign MS).",
    "option_a": "5",
    "option_b": "10",
    "option_c": "15",
    "option_d": "20",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuroimmunology",
    "explanation": "Natalizumab is a highly effective monoclonal antibody used in multiple sclerosis (MS) that works by inhibiting lymphocyte migration into the central nervous system. However, its mechanism predisposes patients to reactivation of latent JC virus, which can cause progressive multifocal leukoencephalopathy (PML). Preventing PML largely depends on risk stratification before treatment initiation. Natalizumab binds to \u03b14-integrin, blocking the adhesion of lymphocytes to vascular endothelium, thereby reducing inflammatory cell entry into the CNS. In patients who have been exposed to the JC virus, this immune modulation may allow reactivation of the virus leading to PML \u2013 a demyelinating disease caused by lytic infection of oligodendrocytes. Screening for JC virus antibodies helps stratify this risk. PML presents with progressive neurological deficits that can mimic MS exacerbations but with a rapid and often fatal course. Clinicians screen for anti\u2013JC virus antibody levels before starting natalizumab to identify patients at higher risk. Before natalizumab initiation, testing the patient\u2019s serum for antibodies to JC virus (and, if available, calculating an index value) is essential. This, along with periodic MRI monitoring, is used to detect early signs of PML. Differential diagnoses include MS relapse, other opportunistic infections, or drug-induced leukoencephalopathy. First-line prevention involves risk stratification with pre-treatment JC virus antibody screening. In patients who are JC virus\u2013antibody negative, natalizumab can be used with periodic re\u2010evaluation. A tiered approach includes: (1) Pre-treatment screening; (2) Regular monitoring (MRI every 6\u201312 months, as recommended in updated guidelines); (3) Discontinuation or switching therapy in patients with high antibody titers. In special populations (pregnant or lactating women), the decision to use natalizumab requires a careful risk\u2013benefit analysis and thorough counseling, as its use is generally reserved for patients with highly active disease, with appropriate monitoring. Option A (Annual MRI) is used for monitoring but does not prevent PML. Options C and D are not provided and/or not relevant. Option B, \u201cPretreatment JC virus titer levels screen,\u201d is the correct preventive measure as it directly assesses the patient\u2019s risk prior to starting the drug. \u2022 JC virus antibody screening is mandatory before starting natalizumab. \u2022 A high JC virus antibody index correlates with increased risk for PML. \u2022 Regular MRI monitoring is essential for early detection of PML but does not prevent it. Recent guidelines emphasize the importance of JC virus antibody index levels along with periodic imaging to mitigate risk. Large cohort studies continue to refine the risk models for PML in natalizumab-treated patients, and current recommendations support individualized risk assessment particularly in women of childbearing potential.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Which one of the following is a feature of optic neuritis due to MS?",
    "option_a": "Papillitis with Papilledema",
    "option_b": "Bilateral ON",
    "option_c": "Pain with eye movements",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroimmunology",
    "explanation": "Natalizumab is a highly effective monoclonal antibody used in multiple sclerosis (MS) that works by inhibiting lymphocyte migration into the central nervous system. However, its mechanism predisposes patients to reactivation of latent JC virus, which can cause progressive multifocal leukoencephalopathy (PML). Preventing PML largely depends on risk stratification before treatment initiation. Natalizumab binds to \u03b14-integrin, blocking the adhesion of lymphocytes to vascular endothelium, thereby reducing inflammatory cell entry into the CNS. In patients who have been exposed to the JC virus, this immune modulation may allow reactivation of the virus leading to PML \u2013 a demyelinating disease caused by lytic infection of oligodendrocytes. Screening for JC virus antibodies helps stratify this risk. PML presents with progressive neurological deficits that can mimic MS exacerbations but with a rapid and often fatal course. Clinicians screen for anti\u2013JC virus antibody levels before starting natalizumab to identify patients at higher risk. Before natalizumab initiation, testing the patient\u2019s serum for antibodies to JC virus (and, if available, calculating an index value) is essential. This, along with periodic MRI monitoring, is used to detect early signs of PML. Differential diagnoses include MS relapse, other opportunistic infections, or drug-induced leukoencephalopathy. First-line prevention involves risk stratification with pre-treatment JC virus antibody screening. In patients who are JC virus\u2013antibody negative, natalizumab can be used with periodic re\u2010evaluation. A tiered approach includes: (1) Pre-treatment screening; (2) Regular monitoring (MRI every 6\u201312 months, as recommended in updated guidelines); (3) Discontinuation or switching therapy in patients with high antibody titers. In special populations (pregnant or lactating women), the decision to use natalizumab requires a careful risk\u2013benefit analysis and thorough counseling, as its use is generally reserved for patients with highly active disease, with appropriate monitoring. Option A (Annual MRI) is used for monitoring but does not prevent PML. Options C and D are not provided and/or not relevant. Option B, \u201cPretreatment JC virus titer levels screen,\u201d is the correct preventive measure as it directly assesses the patient\u2019s risk prior to starting the drug. \u2022 JC virus antibody screening is mandatory before starting natalizumab. \u2022 A high JC virus antibody index correlates with increased risk for PML. \u2022 Regular MRI monitoring is essential for early detection of PML but does not prevent it. Recent guidelines emphasize the importance of JC virus antibody index levels along with periodic imaging to mitigate risk. Large cohort studies continue to refine the risk models for PML in natalizumab-treated patients, and current recommendations support individualized risk assessment particularly in women of childbearing potential.",
    "exam_year": "2023",
    "exam_type": "Part I"
  }
]